All articles tagged with #insulin independence
A small stem cell trial using zimislecel by Vertex Pharmaceuticals has temporarily cured or significantly reduced insulin dependence in 10 out of 12 severe Type 1 diabetes patients, offering hope for future treatments.
A new stem cell treatment developed by Vertex Pharmaceuticals shows promise in curing severe type 1 diabetes, with a clinical trial demonstrating significant improvements and reduced insulin dependence in most participants, though further studies are needed to confirm long-term benefits.
Scientists in China have successfully used reprogrammed fat cells, known as chemically induced pluripotent stem-cell-derived islets (CiPSCs), to treat a patient with type 1 diabetes, eliminating the need for insulin 75 days post-procedure. This innovative approach, detailed in the journal Cell, has shown lasting effects one year later, prompting calls for further clinical studies. The treatment's success could potentially revolutionize diabetes care, though its adoption in the U.S. remains uncertain due to regulatory hurdles.
Chinese scientists have reported a potential cure for diabetes using innovative cell therapy, successfully treating a 59-year-old man with type 2 diabetes who became insulin-independent within eleven weeks of a cell transplant. The patient has remained medication-free for over 33 months, marking a significant breakthrough, though further large-scale trials are needed to confirm the treatment's efficacy and safety.
CellTrans, a small biotech company, has become the first to receive FDA approval for a cell therapy, known as Lantidra, for the treatment of type 1 diabetes. Lantidra, administered via an infusion into the liver, aims to provide insulin independence for adults with type 1 diabetes who struggle to achieve target glucose levels. The therapy is made from pancreatic cells sourced from deceased donors and requires the use of immunosuppressive drugs. While some patients have experienced insulin independence for several years, there are risks associated with chronic immunosuppression. Other companies, such as Vertex Pharmaceuticals and Eli Lilly, are also developing cell therapies for type 1 diabetes.
A company named Vertex has successfully created beta cells from stem cells, offering hope for a potential cure for type 1 diabetes. In human trials, half-doses of these stem cell-derived beta cells were given to two patients experiencing severe hypoglycemia. One patient became insulin independent, while the other showed some activity but not enough for independence. Four more patients received a full dose, with one achieving insulin independence after a year. All six patients showed positive responses to the treatment, producing insulin and exhibiting positive C-peptide levels. The trial will now expand to include more patients, although the small sample size and variation in response highlight the need for further research. Side effects were related to immunosuppression. Overall, this development process shows promise for future therapies in treating type 1 diabetes.